Cambrex Corporation (NYSE:CBM) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Thursday.

Several other research firms also recently weighed in on CBM. Zacks Investment Research downgraded shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. ValuEngine downgraded shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $64.00.

Cambrex Corporation (NYSE:CBM) traded down 4.04% on Thursday, reaching $49.85. 355,637 shares of the company’s stock were exchanged. The company has a market cap of $1.63 billion, a P/E ratio of 18.16 and a beta of 2.28. The firm has a 50 day moving average of $56.43 and a 200-day moving average of $55.37. Cambrex Corporation has a 12-month low of $38.30 and a 12-month high of $62.95.

Cambrex Corporation (NYSE:CBM) last released its earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share for the quarter, hitting the consensus estimate of $0.76. The business had revenue of $134.55 million for the quarter, compared to the consensus estimate of $136.82 million. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The firm’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same period last year, the firm posted $0.68 earnings per share. Equities analysts expect that Cambrex Corporation will post $3.08 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “BidaskClub Downgrades Cambrex Corporation (CBM) to Sell” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/27/bidaskclub-downgrades-cambrex-corporation-cbm-to-sell.html.

In related news, VP Samantha Hanley sold 14,000 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $57.56, for a total transaction of $805,840.00. Following the transaction, the vice president now directly owns 1,500 shares of the company’s stock, valued at $86,340. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $54.19, for a total transaction of $650,280.00. Following the transaction, the chief executive officer now directly owns 95,328 shares in the company, valued at $5,165,824.32. The disclosure for this sale can be found here. Insiders have sold 70,656 shares of company stock worth $4,064,423 over the last ninety days. 2.48% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in CBM. Flinton Capital Management LLC increased its position in shares of Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares during the last quarter. Creative Planning increased its position in shares of Cambrex Corporation by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,093 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Cambrex Corporation by 9.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after buying an additional 150 shares during the last quarter. YorkBridge Wealth Partners LLC increased its position in shares of Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new position in shares of Cambrex Corporation during the first quarter worth approximately $109,000. 98.28% of the stock is currently owned by hedge funds and other institutional investors.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.